Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04414904

Determining the Reproductive Health of Men Post-COVID-19 Infection

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Imperial College London · Academic / Other
Sex
Male
Age
18 Years – 50 Years
Healthy volunteers

Summary

Study rationale 1. An increasing proportion of the worldwide population is being infected with COVID-19. 2. There are ongoing and currently unanswered safety concerns about the effects of COVID-19 on reproductive health. 3. It will be immensely reassuring to rapidly report that COVID-19 has no detectable effects on male endocrine or sperm function. Conversely, if COVID-19 does impair male reproductive health, appropriate screening can be performed in couples trying to conceive, and further research can be undertaken. 4. The proposed study will be simple, rapid, and authoritative for the UK and worldwide.

Detailed description

Male infertility results from impaired sperm function, and account for half of all infertility. Fertility services have been reported to cost £325M annually in the UK(4) (REF). Testosterone deficiency is one of the most common hormonal problems affecting men, leading to osteoporosis, type 2 diabetes, obesity and depression(5). Concerns have been raised about the potential effects of COVID-19 on male reproductive dysfunction (male infertility and testosterone deficiency). A recent study has suggested that COVID-19 may enter human cells by binding to receptors (special gates on cells that recognise a specific molecule) for angiotensin converting enzyme 2 (ACE2)(6) . ACE2 receptors are found at very high levels in the testes. Within the testes, ACE2 is found on developing sperm, the 'nurse cells' that help the sperm grow (Sertoli cells), and also on Leydig cells which are needed to make the male sex hormone testosterone. In summary, this evidence suggests that there is a plausible link why COVID-19 would cause male infertility and testosterone deficiency. All fertility treatment in the UK is regulated by the Human Fertility and Embryology Authority (HFEA). The HFEA has prohibited on all non-cancer fertility treatment in the UK between April 15th and May 12th 2020 due to the COVID-19 epidemic. It is important to rapidly screen and report whether COVID-19 has any obvious effects in causing male infertility and testosterone deficiency. It must be noted that a recent study(1) reported that COVID-19 is not spread by human semen and therefore, semen processing should not risk staff to COVID-19 infection.

Conditions

Interventions

TypeNameDescription
OTHERExposure: Covid-19 infectionPrevious history of COVID-19 infection.

Timeline

Start date
2020-06-10
Primary completion
2020-06-10
Completion
2020-06-10
First posted
2020-06-04
Last updated
2020-11-24

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT04414904. Inclusion in this directory is not an endorsement.